Loading...
Back to narrative

ROSSARI: Capacity Expansion And Saudi Subsidiary Investment Will Drive Future Upside

ROSSARI: New Expansion Projects Will Drive Global Market Penetration

ROSSARI logo
ROSSARI
AnalystConsensusTarget
Not Invested
Published 10 Feb 2025

Update shared on 06 Dec 2025

Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-28.2%
7D
-2.7%

Narrative Update on Rossari Biotech

Analysts have maintained their price target for Rossari Biotech at ₹795.75, citing largely unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples. Taken together, these factors suggest limited change in the company’s fundamental outlook.

What's in the News

  • Commissioned an additional 20,000 MTPA capacity at the Dahej facility, taking total installed capacity to 1,52,500 MTPA. This is intended to support growth in personal care, agrochemicals, oil and gas, and pharma segments (company update).
  • Completed Phase 1 of ethoxylation expansion at Unitop with 15,000 MTPA commissioned, bringing current installed ethoxylation capacity to 51,000 MTPA. Phase 2 of the 30,000 MTPA plan is targeted for commissioning by the third quarter of fiscal 2026 (company update).
  • The board approved an investment of up to USD 8 million in tranches in Rossari International Limited Company, a wholly owned subsidiary in Saudi Arabia, to evaluate and support a potential international expansion plan (board decision).
  • A board meeting is scheduled for October 15, 2025, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2025 (regulatory filing).

Valuation Changes

  • Fair Value: Unchanged at ₹795.75 per share, indicating a stable intrinsic value estimate.
  • Discount Rate: Edged down marginally from 13.63 percent to 13.63 percent, a negligible change in the cost of capital assumptions.
  • Revenue Growth: Maintained at approximately 15.30 percent, reflecting no material revision to long term growth expectations.
  • Net Profit Margin: Essentially flat at around 7.40 percent, suggesting stable profitability assumptions.
  • Future P/E: Nearly unchanged at about 25.48x, indicating consistent expectations for the company’s forward valuation multiple.

Have other thoughts on Rossari Biotech?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.